Elisa Agostinetto· @ElisaAgostinett · X·· 1 天前评分90
正文 · 机器翻译
#ESMO26 #breastcancer 入选论文口头报告 2️⃣
@antgiorda 介绍 FOURLIGHT-1
Atirmociclib (CDK4i) + fulvestrant 用于 CDK4/6i 治疗后 PD 的 HR+ aBC ⬆️ PFS（差异为 3 个月）
Atirmociclib 一线治疗的 ph3 试验正在进行
@OncoAlert
187 浏览 · 5 赞 · 6 转发 · 0 回复
会议摘要
1842O按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgFOURLIGHT-1
https://esmocongress.esmo.org来源：Elisa Agostinetto · x.com